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ABSTRACT
Chronic wounds are a major global health problem. Their management is difficult
and costly, and the development of antibiotic resistance by both planktonic and
biofilm-associated bacteria necessitates the use of alternative wound treatments.
Honey is now being revisited as an alternative treatment due to its broad-spectrum
antibacterial activity and the inability of bacteria to develop resistance to it. Many
previous antibacterial studies have used honeys that are not well characterized, even
in terms of quantifying the levels of the major antibacterial components present,
making it difficult to build an evidence base for the efficacy of honey as an antibiofilm
agent in chronic wound treatment. Here we show that a range of well-characterized
New Zealand manuka-type honeys, in which two principle antibacterial compo-
nents, methylglyoxal and hydrogen peroxide, were quantified, can eradicate biofilms
of a range of Staphylococcus aureus strains that differ widely in their biofilm-forming
abilities. Using crystal violet and viability assays, along with confocal laser scanning
imaging, we demonstrate that in all S. aureus strains, including methicillin-resistant
strains, the manuka-type honeys showed significantly higher anti-biofilm activity
than clover honey and an isotonic sugar solution. We observed higher anti-biofilm
activity as the proportion of manuka-derived honey, and thus methylglyoxal, in a
honey blend increased. However, methylglyoxal on its own, or with sugar, was not
able to effectively eradicate S. aureus biofilms. We also demonstrate that honey was
able to penetrate through the biofilm matrix and kill the embedded cells in some
cases. As has been reported for antibiotics, sub-inhibitory concentrations of honey
improved biofilm formation by some S. aureus strains, however, biofilm cell suspen-
sions recovered after honey treatment did not develop resistance towards manuka-
type honeys. New Zealand manuka-type honeys, at the concentrations they can be
applied in wound dressings are highly active in both preventing S. aureus biofilm
formation and in their eradication, and do not result in bacteria becoming resistant.
Methylglyoxal requires other components in manuka-type honeys for this anti-
biofilm activity. Our findings support the use of well-defined manuka-type honeys as
a topical anti-biofilm treatment for the effective management of wound healing.
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INTRODUCTION
Chronic wounds currently affect 6.5 million people in the US. These wounds are difficult
to treat and estimated to cost in excess of US $25 billion annually, with significant increases
expected in the future (Sen et al., 2009). A wound is generally considered chronic if it has
not started to heal by four weeks or has not completely healed within eight weeks (McCarty
et al., 2012). Such prolonged, non-healing wounds are caused by a variety of factors, with
bacterial infection being a significant contributor.
In chronic wounds, as with everywhere on earth, bacterial cells predominantly exist
as biofilms, where cells are embedded within a matrix of polysaccharides and other
components. This matrix affords resistance to environmental stresses such as altered pH,
osmolarity, and nutrient limitation (Fux et al., 2005). The matrix also limits access of
antibiotics to the biofilm embedded cells (Ranall et al., 2012), which are up to 1,000 times
more recalcitrant to these compounds than planktonic cells (Hoyle & Costerton, 1991).
Planktonic bacteria may also contribute to pathogenesis, as their release from biofilms has
been proposed to maintain the inflammatory response within the wound (Ngo, Vickery
& Deva, 2012; Wolcott, Rhoads & Dowd, 2008), as well as allowing seeding to other areas
(Battin et al., 2007; Costerton et al., 2003). Along with the difficulties of treating biofilm in-
fections, the emergence of resistance to multiple antibiotics has exacerbated the problem of
chronic wound treatment (Engemann et al., 2003; Projan & Youngman, 2002). Thus, there
is an increasing need for new approaches to combat bacterial biofilms in chronic wounds.
Honey has been used to treat acute and chronic wound infections since 2500 BC
(Forrest, 1982; Molan, 1999; Simon et al., 2009). Honey possesses a number of antimicrobial
properties including high sugar content, low pH, and the generation of hydrogen peroxide
by the bee-derived enzyme glucose oxidase (Stephens et al., 2009). However, not all honeys
are the same and their antimicrobial properties vary with floral source, geographic
location, weather conditions, storage (time and temperature) and various treatments,
such as heat (Al-Waili et al., 2013; Allen, Molan & Reid, 1991; Molan, 1999; Sherlock et al.,
2010). These factors lead to differences in the levels of various antibacterial components.
Manuka honey is derived from Leptospermum scoparium bush and is particularly potent
(Adams et al., 2008; Allen, Molan & Reid, 1991; Kwakman et al., 2011). This is believed to be
largely due to the high levels of the reactive dicarbonyl methylglyoxal (MGO) (Adams et al.,
2008; Mavric et al., 2008), which is highly inhibitory to bacterial growth (Lu et al., 2013).
Other antimicrobial compounds in honeys include bee defensin-1 (Kwakman et al., 2010;
Kwakman & Zaat, 2012), various phenolic compounds and complex carbohydrates (Adams
et al., 2008; Gresley et al., 2012; Mavric et al., 2008; Molan, 1999; Weston, Brocklebank & Lu,
2000). The combination of these diverse assaults may account for the inability of bacteria to
develop resistance to honey (Blair et al., 2009; Cooper et al., 2010), in contrast to the rapid
induction of resistance observed with conventional single-component antibiotics (Colsky,
Kirsner & Kerdel, 1998; Cooper, 2008).
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A few studies have examined the effect of manuka honey on biofilms, showing it
to be active against a range of bacteria, including Group A Streptococcus pyogenes,
Streptococcus mutans, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae
and Staphylococcus aureus (Alandejani et al., 2008; Maddocks et al., 2013; Maddocks et
al., 2012; Majtan et al., 2013). However, the levels of reported anti-biofilm activity are not
consistent among these studies. This is highly likely to be at least in part due to differences
in the levels of the principle antibacterial components in the honey, MGO and hydrogen
peroxide, which varies with the floral and geographic source of nectar, the honey storage
time and conditions, and any possible other treatments that may have occurred. All these
conditions affect the antimicrobial activity of honey (Adams et al., 2008; Al-Waili, Salom
& Al-Ghamdi, 2011; Sherlock et al., 2010; Stephens et al., 2009), but are often not reported.
Importantly, medical-grade honeys, while often composed primarily of manuka, can
also contain honey derived from other flora sources, which can alter the levels of various
antimicrobial components. Therefore, it is imperative to use well-characterized honeys
to enable both accurate comparisons among studies, and the rigorous assessment of the
potential of medical-grade honey to be used in wound treatment in the clinic.
Here we have performed biomass and viability assays, as well as confocal scanning light
microscopy to examine the anti-biofilm activity of four NZ manuka-type honeys, clover
honey and an isotonic sugar solution on a range of S. aureus strains that differ widely in
their biofilm-forming ability. These honeys have been well characterized in terms of their
geography, floral source and the level of the two principal antibacterial components found
in honey, MGO and hydrogen peroxide. We demonstrate that the manuka-type honeys
are highly active in both the prevention and elimination of methicillin-sensitive and
methicillin-resistant S. aureus biofilms. The antibiofilm activity was highest in the honey
blend that contained the highest level of manuka-derived honey; although the same level
of MGO, with or without sugar, could not eradicate biofilms. This suggests that additional
factors in these manuka-type honeys are responsible for their potent anti-biofilm activity;
and emphasise the importance of characterizing honey in order to understand and choose
the best honey product for wound management.
MATERIALS AND METHODS
Honey samples
The New Zealand (NZ) honey samples used in this study are listed in Table 1, and
include monofloral manuka honey, Medihoney (a manuka-based medical grade honey;
Comvita NZ Ltd), a manuka/kanuka blend, and clover honey (a white New Zealand
honey). All honey samples were supplied by Comvita NZ Ltd. (Te Puke, New Zealand).
The harvesting and geographic information for these honeys, as well as the levels of the
three major antimicrobial components: methylglyoxal (MGO), di-hydroxyacetone (DHA)
and hydrogen peroxide, are listed in Table 1. All samples were stored in the dark at 4 ◦C and
were freshly diluted in Tryptone Soya Broth (TSB) immediately before use in assays. All
honey concentrations are expressed as % w/v.
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Table 1 Harvesting and chemical information for the tested NZ honey samples.
Honey type Harvest period Area Floral source Major antimicrobial composition
DHAa MGOa H2O2b
Manuka Spring 2010 Hokianga, Northland, NZ Leptospermum scoparium var.
incanum
4277 958 0.34
Medihoney Spring 2010 Northland, NZ Leptospermum scoparium var.
incanum + Kunzea ericoides
883 776 0.31
Manuka/kanuka Summer 2010/11 Hokianga, Northland, NZ Leptospermum scoparium var.
incanum + Kunzea ericoides
652 161 0.68
Clover N/A* Balcutha, Otago, NZ Trifolium spp. <20 <10 0.11
Notes.
a MGO (methylglyoxal) levels were analyzed against di-hydroxyacetone (DHA) and expressed as mg MGO per kg of honey.
b Rate of production of H2O2 (hydrogen peroxide) is expressed as µmol/h in 1 mL of 10% w/v honey.
* Information not available.
Other tested solutions
A series of other solutions were included for investigation alongside the honey samples:
(i) a sugar solution designed to mimic the concentration and composition of honey sugars
(45% glucose, 48% fructose, 1% sucrose) diluted as above for honey; (ii) MGO diluted in
TSB to concentrations similar to those present in the manuka-type honeys (100 mg/kg,
700 mg/kg and 900 mg/kg honey) to assess the effect of MGO alone on bacterial growth;
(iii) MGO diluted in sugar solution to the same concentration as (ii). MGO was obtained
as a∼40% (w/w) solution in water (Sigma-Aldrich Co., MO, USA).
Hydrogen peroxide assay
The level of hydrogen peroxide produced by the NZ honey samples was determined using a
hydrogen peroxide/peroxidase assay kit (Amplex Red; Molecular Probes, Life Technologies
Corp., Carlsbad, CA, USA) as previously reported (Lu et al., 2013).
Bacterial strains and growth conditions
Four strains of S. aureus were examined. These include two laboratory reference strains:
NCTC 8325 (National Collection of Type Cultures) (Stepanovic et al., 2000) and ATCC
25923 (American Type Culture Collection) which are methicillin-sensitive, and two
clinical isolates: MW2 (Hospital-Acquired Methicillin-resistant Staphylococcus aureus,
HA-MRSA) (Baba et al., 2002) and USA300 (Community-Acquired Methicillin-resistant
Staphylococcus aureus, CA-MRSA) (Kazakova et al., 2005). All S. aureus strains were grown
in TSB at 37 ◦C. For optimal biofilm formation, 1% (w/v) glucose was added to this
medium (TSBG) except for strain NCTC 8325 which was found to produce optimal
biofilm in the absence of added glucose.
Susceptibility of S. aureus to NZ honeys: growth response assays
In this study, growth response assays were carried out to assess whether the NZ honeys
affected cell growth of the different strains of S. aureus (at concentrations of 1–32%;
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prepared as serial 2-fold dilutions in TSB(G)). Details of the growth assay methods are
described in our previous publication (Lu et al., 2013). TSB(G) media without honey
was included as a control. Unless otherwise stated, all assays were performed with three
biological replicates and three technical repeats of each replicate.
Biofilm formation assays
The effects of NZ honeys and other solutions on S. aureus biofilm formation were
determined using crystal violet static biofilm formation assays in microtitre plates
according to published studies with the following modifications (Christensen et al.,
1985; Stepanovic et al., 2000). Crystal violet stains all biomass including live and dead
cells and the biofilm matrix. S. aureus strains were cultured in 2 mL of TSB(G) with
shaking (250 rpm) overnight at 37 ◦C . A suspension from the overnight culture was
then diluted to a cell density of approximately 107 CFU/mL in fresh TSB containing the
appropriate test solution (honey, sugar solution, MGO or MGO in combination with
sugar) to give a final volume of 150 µL. The suspension was added to each well of a 96-well
tissue-culture treated microtitre plate (BD Falcon, NJ, USA). Media-only and media with
the appropriate test solution without S. aureus inoculation were included as negative
controls. The microtitre plates were sealed with AeraSeal (Excel Scientific, CA, USA) and
incubated in a humidified incubator for 24 h at 37 ◦C. Following this, planktonic cell
growth was assessed by transferring the planktonic phase into a new 96-well microtitre
plate and reading the optical density at 595 nm with a microplate reader (VersaMax,
Molecular Devices, California, USA). This step was required as S. aureus forms biofilms
on the bottom of the microtitre plate wells, which interferes with optical density readings
of the planktonic culture. The microtitre plates with residual biofilm were then washed
three times with sterile phosphate buffered saline (PBS) to remove unattached cells and
air-dried at 65 ◦C for 1 h, to fix the S. aureus biofilm to the bottom of the well surface. The
plate was then stained with 0.2% (w/v) crystal violet at room temperature for 1 h, excess
crystal violet solution was decanted and the plates were washed as above with PBS. Stain
that was bound to the adherent biomass was resolubilized with 200 µL 33% acetic acid and
transferred into a new 96-well microtitre plate to measure the OD595.
Biofilm elimination assays
S. aureus biofilms were first formed in the wells of a 96-well microtitre plate for 24 h
at 37 ◦C as described above. Biofilms were then washed three times with PBS. Various
concentrations (0%–32% in two-fold serial dilutions) of honey and other test solutions
were then added to the established S. aureus biofilms. The assay plates were then incubated
for a further 24 h at 37 ◦C, and planktonic cell growth and biofilm mass were quantified as
described above.
Determination of bacterial cell viability in biofilms
Crystal violet stains all the components of the biofilm (Bauer et al., 2013). To quantify
the viability of cells within the S. aureus biofilms following honey treatment, we used a
BacTitre Glo Microbial Cell Viability Assay Kit (Promega, WI, USA), which measures
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ATP levels as a proxy for viability. The assay reagents lyse the bacterial cells to release
intracellular ATP, the levels of which are quantified via a luminescence-based luciferase
activity assay (Haddix et al., 2008; Junker & Clardy, 2007). The BacTitre Glo protocol
involved the same steps as crystal violet staining (above), however, instead of drying
and staining the biofilms, plates were incubated with BacTitre Glo reagent in TSB(G)
for 10 min at 37 ◦C in the dark. The contents of each well were then transferred into
white solid-bottom 96-well microtitre plates (Cellstar; Greiner Bio-one, France) for
luminescence measurement. Luminescence, which is proportional to the amount of ATP
produced by metabolically active cells, was recorded using a 96-well microplate reader
(Infinite 200Pro; TeCan, Ma¨nnedorf, Switzerland).
To ensure the validity of this assay, a standard curve was constructed to assess the
correlation between bacterial cell numbers and the luminescent signal in the biofilm.
This was performed on the untreated control (containing S. aureus in TSB(G) only).
Biofilms produced as above were washed and cells within the biofilm dispersed using a
small probe sonicator (Sonics and Materials VC-505) to enable quantification by direct
enumeration (Merritt, Kadouri & O’Toole, 2005). The recovered cell suspension was serially
diluted 10-fold and a 20 µL aliquot was plated on Tryptone Soya Agar (TSA) for CFU
determination. Luminescence of cells in the remaining suspension was assessed using
the BacTitre Glo kit. From this, a correlated standard curve was constructed between
calculated CFU/well and the relative luminescence readings. According to the standard
curve shown in Fig. 1, the detection limit of the BacTitre Glo is at a luminescence reading
below 1,000, which is equivalent to 103 CFU/well (linear range from 103–107 CFU/well).
An upper limit was not detected.
Visualizing live/dead stained S. aureus biofilms using confocal
laser scanning microscope (CLSM)
S. aureus biofilms were treated with TSB containing 1%, 2%, 16%, and 32% NZ honeys or
sugar solution for 24 h in black polystyrene 96-well microtitre plates with µClear bottoms
(Cellstar; Greiner Bio-One, France) as described above, except the biofilm mass was not
fixed by air-drying. The treated biofilm mass was washed three times with PBS and cells
within the biofilm structure were fluorescently stained with 2.5 µM Syto9 (Invitrogen, CA,
USA) and 4.3 µM propidium iodide (PI) (Becton Dickinson, NJ, USA), which identify
live and dead cells in the biofilm structure, respectively. After 30 min of incubation in the
dark at room temperature, the wells were washed thoroughly with PBS and fixed with 4%
paraformaldehyde (Sigma-Aldrich, MO, USA) for 15 min. The wells were then rinsed and
stored in PBS for imaging. Biofilms were imaged using confocal laser scanning microscopy
imaging (CLSM) on a Nikon A1 confocal microscope. The Syto9 and PI fluorophores
were excited at 488 nm and 561 nm, and the emissions were collected at 500–550 nm
and 570–620 nm, respectively. For quantitative analysis, at least eight separate CLSM
image stacks of each NZ honey treated biofilms were acquired with a resolution of 512×
512 pixels. Biofilm biomass was calculated using COMSTAT (Heydorn et al., 2000) and
is expressed as volume of the biofilm over the surface area (µm3/µm2). Representative
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Figure 1 Correlation of levels of intracellular ATP to colony forming units (CFU) in static biofilms of
S. aureus. Static biofilms of S. aureus were formed in the wells of a microtitre plate for 48 h (with media
replenishment at 24 h). After removal of the biofilm from the wall of each well, intracellular ATP levels
were measured by the BacTitre Glo Viability Kit and CFU were determined for each well. The intracellular
levels of ATP are plotted as a function of CFU and validate that the BacTitre Glo Viability Kit can be used
as a surrogate measure of biofilm cell viability in subsequent assays.
presentation image stacks of each treatment were acquired at a resolution of 1024 ×
1024 pixels and three dimensional biofilm images reconstructed using NIS-elements
(Version10, Nikon Instruments Inc., USA). It should be noted that due to the incomplete
displacement of Syto9 by propidium iodide in dead cells that there will remain some Syto9
staining of dead cells. Therefore the absolute level of live cells detected in the Syto9 channel
will be somewhat overestimated using this co-staining method (Stocks, 2004).
Assaying honey resistance in cells recovered from biofilms
The development of resistance is a great concern in clinical settings, where bacteria can
become resistant to inhibitory compounds after exposure to sub-inhibitory concentrations
(Cars & Odenholt-Tornqvist, 1993; Pankuch, Jacobs & Appelbaum, 1998). Planktonic cells
that appeared after 24 h manuka-type honey treatment of established biofilms were
assumed to have been released from the biofilm matrix. Cells recovered from biofilms
treated with sub-eliminatory concentrations of manuka-type honeys were collected and
tested for their ability to grow and form biofilms under the static growth conditions
described above. Cell growth and biofilm formation were defined as not detected when
the OD(x)–OD(media only blank) ≤ 0.1. Each experiment was performed with three biological
replicates and three technical repeats of each biological replicate.
Statistical analysis
Statistical analysis to determine significant differences between treatments and among
honey samples were performed. First, data sets were checked for normality (Gaussian
Distribution) using the D’Agostino-Pearson normality test (alpha = 0.05) in GraphPad
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Table 2 Concentration of honey required to inhibit S. aureus growth.
Honeys NCTC 8325 ATCC 25923 MW2 USA300
Manuka honey 8* 8 8 8
Medihoney 8 8 8 8
Manuka/kanuka honey 16 16 16 16
Clover honey 32 32 32 32
Sugar solution >32 >32 32 >32
Notes.
* All numbers in the table are honey concentrations (%, w/v).
Prism (versions 5 and 6). Once normality was confirmed, significant differences between
treatments and among honey samples were performed using One-Way ANOVA with Tukey
Test using the same software. Statistical significance was set at p < 0.05.
RESULTS
The effect of NZ manuka-type honeys on the planktonic growth of
S. aureus
Planktonic growth and biofilm mass were assessed to examine the ability of four NZ
honeys, three manuka-types and one clover, and a sugar solution to prevent biofilm
formation by different strains of S. aureus. Following 24 h incubation under static
conditions, S. aureus cells formed biofilms at the bottom of microtitre plates, with very
little or no planktonic growth detected, indicating that the concentration of honey
needed to prevent S. aureus planktonic cell growth could not be calculated under these
conditions. Shaking broth cultures were instead used to assess the effect of the treatments
on planktonic growth. The results are shown in Table 2. Planktonic growth of the four
S. aureus strains, NCTC 8325, ATCC 25923, MW2 and USA300, was completely inhibited
by 8% manuka honey and Medihoney, 16% manuka/kanuka honey and 32% clover honey.
The 32%, sugar solution was only effective at inhibiting growth of the MRSA strain MW2,
with no inhibition of growth of the other strains at the concentrations tested (1–32%).
These data are in agreement with the results of our previous study using the standard
S. aureus reference strain, ATCC 25923, which used a similar suite of honey types and the
same experimental conditions (Lu et al., 2013).
The effect of NZ manuka-type honeys on S. aureus
biofilm formation
All strains of S. aureus were assessed for their biofilm-forming ability after 24 h and 48 h.
Under static conditions, biofilm-forming ability varied between strains, with NCTC 8325
forming the most robust biofilms, and generating significantly more biofilm mass than
the other three tested strains (Figs. 2A and 2B). This was followed by ATCC 25923 and
USA300, with MW2 forming the thinnest biofilms (Figs. 2A and 2B; p < 0.05). The
effects of the four NZ honeys and the sugar solution on biofilm formation of strain NCTC
8325 are shown in Fig. 3A. Manuka honey was the most effective at preventing biofilm
formation by S. aureus NCTC 8325, resulting in ∼95% reduction (p < 0.001) in biofilm
Lu et al. (2014), PeerJ, DOI 10.7717/peerj.326 8/25
Figure 2 Quantification of biofilm formation by different strains of S. aureus. The ability of different
strains of S. aureus to form biofilms on the plastic surface of tissue-culture treated 96-well microtitre
plate was assessed in TSB(G) at 24 h and 48 h. Biofilm adherence was determined using a static biofilm
formation assay over 24 h (A) and 48 h (with media replenished after 24 h incubation) (B). Biofilm
formation was quantified by staining with 0.2% crystal violet solution and measured at an optical density
of 595 nm. Error bars represent ±standard deviation (SD) of three biological samples performed in
triplicate, *** represents p < 0.001, compared to NCTC 8325, as assessed by One-Way ANOVA with
Tukey test after confirming normality of the data set for each treatment using the D’Agnostino-Pearson
normality test.
formation at 8% (Fig. 3A) compared to the untreated (0%) control. At this concentration,
the other honeys and the sugar solution did not significantly reduce biofilm formation.
Medihoney and manuka/kanuka honey were highly effective at 16%, preventing biofilm
formation by ∼95% (p < 0.001). Clover honey was much less active and was less able to
prevent biofilm formation than the sugar solution, even at the highest concentration used
(32%).
For NCTC 8325, the addition of sub-inhibitory concentrations of manuka and
manuka/kanuka honey significantly enhanced biofilm formation, increasing it by 1.5-
and 2-fold, compared to the untreated control (p < 0.001). In contrast, Medihoney, clover
honey and the sugar solution did not enhance biofilm formation by strain NCTC 8325 at
any concentration tested.
S. aureus strain ATCC 25923, which is a standard clinical reference strain, produced
similar results to NCTC 8325, including the enhancement of biofilm formation following
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Figure 3 Effects of NZ honeys and sugar on S. aureus biofilm formation. S. aureus biofilms were
allowed to form in the presence of four different NZ honey types (manuka, Medihoney, manuka/kanuka
or clover) or a sugar solution. Biofilm formation was assessed using a static biofilm formation assay
with crystal violet staining to quantify biomass. S. aureus strains are: (A) NCTC 8325; (B) ATCC 25923;
(C) MW2 (HA-MRSA) and (D) USA300 (CA-MRSA). Biofilm formation is expressed as a percentage
relative to that produced by the untreated control, which is set at 100%. Error bars represent ±standard
deviation (SD) of three biological samples performed in triplicate. Statistical significance (p < 0.05)
was assessed by One-Way ANOVA with Tukey test after confirming normality of the data set for each
treatment using the D’Agnostino-Pearson normality test.
Lu et al. (2014), PeerJ, DOI 10.7717/peerj.326 10/25
sub-inhibitory honey treatment (Fig. 3B). The hospital-acquired MRSA strain MW2—the
weakest biofilm former out of all four tested strains (Figs. 2A and 2B; p < 0.05)—displayed
a very sensitive profile to all of the NZ honeys and the sugar solution at all tested
concentrations (Fig. 3C). Even with only 1% honey or sugar solution, a∼50% reduction in
biofilm formation was observed for MW2 (p < 0.001). At higher concentrations (≥8%),
all four NZ honeys were significantly more effective than the sugar solution at preventing
MW2 biofilms. The other MRSA strain, USA 300, responded similarly to NCTC 8325, with
approximately the same concentrations of manuka-type honey being required to reduce
biofilm formation by∼95%. However, unlike NCTC 8325, sub-inhibitory concentrations
of manuka-type honey reduced biofilm formation of USA 300 rather than enhancing
it (e.g., 4% manuka-type honeys exhibited ∼50–80% biofilm inhibition of USA 300).
Moreover, in USA300, biofilm formation was not affected by the sugar solution at any
tested concentration.
The results above can be summarize as follows: (i) all three manuka-type honeys are
effective at inhibiting biofilm formation of a range of of MSSA and MRSA strains; with
(monofloral) manuka honey being generally more effective than the other maunka-type
honeys; and (ii) the manuka-type honeys are generally more effective than clover honey
and the isotonic sugar solution, although clover honey was just as inhibitory as the
manuka-type honeys for the weakest biofilm former, S. aureus MW2.
The effect of MGO on S. aureus biofilm prevention
MGO is a principle antibacterial component of manuka honey responsible for its
inhibitory effects on the growth of S. aureus and other bacterial species. This is evidenced
by the correlation between the MGO level and the proportion of manuka-derived honey
in a honey blend (Jervis-Bardy et al., 2011; Lu et al., 2013). To determine whether MGO is
solely responsible for the inhibitory effect of the three manuka-type honeys on S. aureus
biofilm formation, biofilm assays were performed using MGO at equivalent concentrations
to those present in each of the manuka-based honey samples, with and without the
addition of the sugar solution (Fig. 4). S. aureus NCTC 8325 biofilm formation was not
significantly (p > 0.05) affected by MGO at concentrations equivalent to that present in
1–16% manuka-type honeys. MGO at medium (700 mg/kg) and high (900 mg/kg) levels
at the equivalent concentration to 32% manuka-kanuka honey and Medihoney prevented
approximately 50% and 75% biofilm formation, respectively (p < 0.05). The addition of
the sugar solution to MGO at the same levels present in 16% of all three manuka-type
honeys, led to a dramatic decrease (∼95%) in biofilm formation.
The effect of NZ manuka-type honeys on established S. aureus
biofilms
Bacterial biofilms are usually already established in open, chronic wounds prior to
presentation to the clinic for medical treatment. We therefore assessed the ability of the
four NZ honeys to remove established biofilms produced by the four strains of S. aureus.
These results are presented in Fig. 5, with coloured lines showing biofilm mass present
following treatment with different concentrations of the various honey types. While
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Figure 4 Effects of MGO on S. aureus biofilm formation. Biofilm formation by S. aureus NCTC 8325
grown in the presence of MGO and MGO plus sugar solution. MGO stock solutions were prepared to
correspond to the MGO levels in undiluted manuka-type honeys (100 mg/kg of manuka/kanuka honey,
700 mg/kg of Medihoney, and 900 mg/kg of manuka-honey; Table 1). Biofilm formation was assessed
using the described static assay with crystal violet staining to quantify biomass. Biofilm formation is
expressed as a percentage relative to the untreated control, which is set at 100%. Error bars represent
±standard deviation (SD) of three biological samples performed in triplicate. Statistical significance
(p < 0.05) was assessed by One-Way ANOVA with Tukey test after confirming normality of the data
set for each treatment using the D’Agnostino-Pearson normality test.
there was variation among the S. aureus strains in their response to the different honeys,
there are some important general trends. First, manuka honey was consistently the most
effective at removing biofilm, eliminating almost all of the established S. aureus biofilms
at concentrations of 16%–32%, (p < 0.001 compared to the untreated control sample;
Fig. 5 top panel, orange lines). Second, Medihoney and manuka/kanuka honey were also
effective at these concentrations for some S. aureus strains, but only consistently effective
across all four strains at 32% (Fig. 5, blue and green lines). Third, both the clover honey
and the sugar solution did not significantly reduce (p > 0.5) established biofilm mass until
their concentration reached 32%. However, the sugar solution did not remove the USA 300
biofilm, with no significant reduction in biofilm mass at 32% (Fig. 5, purple line).
NCTC 8325, the most efficient biofilm former out of all tested strains, gave a slightly
different response toward honey treatment compared to the other three strains. Significant
biofilm enhancement occurred in this strain at sub-inhibitory concentrations of manuka
honey (1–2%) and manuka/kanuka honey (1–4%) (p < 0.001; Fig. 5). In addition, this
strain was the least sensitive to the manuka-type honeys. For example, at 8% manuka
honey treatment, the NCTC 8325 biofilm mass remained similar to the untreated control
(p > 0.05; Fig. 5), while the biofilms produced by the other three strains were significantly
reduced at this concentration (p < 0.001; Fig. 5).
The effect of NZ manuka-type honeys on cell viability within
S. aureus biofilms
Elimination of biofilm mass was assessed using crystal violet, a cationic dye that stains
all the components of the biofilm. However, this assay cannot assess the viability of cells
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Figure 5 Effects of NZ honeys on established S. aureus biofilms and cell viability within the biofilms. Established S. aureus NCTC 8325, ATCC
25923, MW2 and USA300 biofilms were treated with NZ honeys – manuka, Medihoney, manuka/kanuka, clover, and a sugar solution. The remaining
biofilm masses were quantified using crystal violet staining (left y-axis) and cell viability within these remaining biofilms were assessed using the
BacTitre Glo Viability Kit (right y-axis). Error bars represent±standard deviation (SD) of three biological samples performed in triplicate Statistical
significance (p < 0.05) was assessed by One-Way ANOVA with Tukey test after confirming normality of the data set for each treatment using the
D’Agnostino-Pearson normality test.
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remaining within the biofilm structure (Bauer et al., 2013). To determine this, we used a
BacTitre Glo assay, which measures ATP levels as a proxy for viability. Side-by-side CFU
measurements showed that the level of ATP detected in these assays was proportional to the
count of viable cells per well (ranging from 103 to 107 CFU/well) (Fig. 1).
The viability of cells remaining in the biofilm after the various treatments is shown
in Fig. 5. In general, cell viability decreased in proportion to the elimination of biofilm
biomass (Fig. 5, black lines). However, several exceptions to this general trend were
observed. In some cases, biofilm biomass increased but cell viability did not, e.g., NCTC
8325 biofilms with low concentrations of manuka (2%) and manuka/kanuka honey
(1–4%) (Fig. 5). In others, biofilm biomass remained relatively constant while cell viability
increased, e.g., NCTC 8325 with 1–4% Medihoney (p < 0.05; Fig. 5), and ATCC 25923
with 4% and 8% clover honey. Another deviation from the general trend was a significant
reduction of cell viability while biofilm biomass remained unaffected, seen for NCTC 8325
and USA 300 with 4% and 8% manuka honey treatment (Fig. 5; p< 0.05). This emphasizes
the importance of assessing viability alongside crystal violet assays for biofilm assessment.
Overall, at concentrations easily attainable in the clinic, the tested four NZ honeys
were effective at eliminating biofilm biomass and at killing both MSSA and MRSA
S. aureus cells in the residual biofilm. Among the honey types, manuka honey was the
most effective, where the elimination of biofilm biomass largely paralleled the reduction
in viability. Following treatment with 8% manuka honey only ∼10% of cells were viable
in the remaining ATCC 25923 and USA 300 biofilms, compared to the untreated control
(i.e., 0% honey), and no generation of ATP could be detected from MW2 (Fig. 5). This
is similar to the degree of biofilm biomass removal, where 85–98% of biofilm biomass
was removed following 8% manuka honey treatment. Although NCTC 8325 biofilm
biomass was seemingly unaffected at 8% manuka honey compared to the untreated control
(Fig. 5), the number of viable cells detected within this biofilm was drastically reduced by
approximately 80% (p < 0.001; Fig. 5).
The effect of MGO on established S. aureus biofilms
To assess the contribution of MGO alone, as well as MGO plus sugar, to biofilm removal,
these components were tested on established S. aureus NCTC 8325 biofilms (Fig. 6). MGO
levels equivalent to the presence of 1–8% manuka/kanuka honey (Table 1) caused biofilm
biomass to increase approximately 2-fold, relative to the untreated control (p < 0.001).
However, the established biofilm biomass was not reduced significantly (p > 0.05), for any
of the tested concentrations (1–32%) of MGO by itself, or in combination with the sugar
solution. Thus, neither MGO nor the combination of MGO with sugar is solely responsible
for the elimination of biofilms observed with these manuka-type honeys.
Visualizing the effects of NZ manuka-type honeys on established
S. aureus biofilms
To assess the effect of the NZ honeys on S. aureus NCTC 8325 biofilms at the cellular level,
we used confocal laser scanning microscopy (CLSM) of biofilms stained with fluorescent
dyes for the detection of live and dead bacteria. This allows both the visualization of
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Figure 6 Effects of MGO on established S. aureus biofilms. S. aureus NCTC 8325 biofilms were treated
with MGO and a combination of MGO and the sugar solution. MGO stock solutions were prepared to
correspond to the MGO levels in undiluted honey (100 mg/kg of manuka/kanuka honey, 700 mg/kg of
Medihoney, and 900 mg/kg of manuka honey; Table 1). The crystal violet stained residual biofilm mass
after 24 h treatment was quantified using optical density (OD595 nm). Error bars represent ±standard
deviation (SD) of three biological samples performed in triplicate. Statistical significance (p < 0.05)
was assessed by One-Way ANOVA with Tukey test after confirming normality of the data set for each
treatment using the D’Agnostino-Pearson normality test.
individual cells within the biofilm in three dimensions and the effect of treatments on cell
viability to be determined. Treatment by sub-inhibitory (1% and 2%) and inhibitory (16%
and 32%) concentrations of NZ honeys was visualized by viewing fluorescently-labelled
live (Syto9; green) and dead (propidium iodide; red) cells. Representative images of each
treatment are presented in Fig. 7 and quantification of live and dead cell biofilm biomass
for several samples for each treatment is shown in Fig. 8. In general, the established
biofilm biomass decreased with increasing concentrations of manuka-type honey. More
specifically, manuka honeys were effective in reducing the live cells in established S. aureus
biofilms. Sub-inhibitory concentrations of all the manuka-type honeys (1% and 2%) and
the sugar solution did not reduce the amount of biomass compared to the non-treated
control cells (Fig. 8). This is shown in Fig. 7 where the untreated control cells displayed a
green (live-cell) lawn that covered nearly the entire surface and this remained following
treatment with 1% and 2% manuka-type honeys. At concentrations of 16% and 32%, the
manuka-type honeys substantially reduced the density and depth of the biofilm, along with
the amount of live cells, compared to the untreated control (Figs. 7 and 8). For example, the
32% manuka honey significantly reduced the Syto9 stained (live) biofilm biomass to 10%
(p < 0.001) compared to the non-treated live biofilm biomass (Fig. 8).
Only small micro-colonies were present following treatment with 32% manuka honey,
and the colour of the biofilms was predominantly yellow (where both the green and red dye
were retained within cells), indicating mostly dead cells. In contrast, 32% clover honey and
sugar solution reduced the total biomass by a maximum of 30% (p < 0.001) compared to
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Figure 7 Live/dead staining of different honey treated established biofilms. Established biofilms
produced by S. aureus NCTC 8325 were treated with TSB containing honey (manuka, Medihoney,
manuka/kanuka or clover) or sugar solution at 1%, 2%, 16%, and 32% (w/vol). Syto9 (green; viable
cells) and propidium iodine (red; dead cells) stained images were acquired using Nikon A1 Confocal
Laser Scanning Microscope. The 3D- images were reconstructed using NIS-elements (version 10). Scale
bar represents 50 µm.
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Figure 8 Quantitative analysis of live/dead stained honey treated biofilms. The established S. aureus
NCTC 8325 biofilm was treated with New Zealand honeys (manuka honey, Medihoney, manuka/kanuka
honey, and clover honey) and a sugar solution at 1%, 2%, 16%, and 32% (w/v) concentrations. Biofilms
were co-stained with Syto9 (S, viable cells) and propidium iodide (P, dead cells) and analyzed using
COMSTAT. The estimated live (S) and dead (P) biomass (volume of the biofilm over the surface area
(µm3/µm2)) are expressed as a percentage of the non-treated control live and dead biomass, which is set
at 100%. Error bars represent ±standard deviation (SD) of three biological samples where eight repre-
sentative images were acquired. Statistical significance (p< 0.05) was assessed by One-Way ANOVA with
Tukey test after confirming normality of the data set for each treatment using the D’Agnostino-Pearson
normality test.
the non-treated control (Fig. 8). This result corresponds to the 3D reconstructed images,
where the Syto9 stained cells remained dominant after treatment (Fig. 7). At 32%, clover
honey or sugar solution, a substantially larger Syto9 stained (live) lawn remained in
comparison to the 32% manuka-type honeys, although the biomass was less confluent
than in the untreated control. These results are consistent with the results obtained with
the crystal violet stained biofilm biomass and ATP viability assays.
Assessing the development of resistance to manuka-type honeys
in S. aureus biofilms
Bacteria that are exposed to sub-inhibitory concentrations of antimicrobial agents
generally develop resistance to these agents (Braoudaki & Hilton, 2004; Davies, Spiegelman
& Yim, 2006). The ability of cells released from S. aureus NCTC 8325 biofilms to develop
resistance after exposure to sub-inhibitory concentrations of honey was investigated, and
the results are summarized in Table 3. All cells recovered from the S. aureus biofilm after
24 h with 8% of all three manuka-type honeys were viable and able to form biofilms
in media (TSB). However, they were unable to grow planktonically when subsequently
exposed to 8% manuka, or 16% Medihoney and manuka/kanuka honey (the MIC levels
for these honeys). Biofilm formation was also inhibited by 8% manuka honey, and by
16% Medihoney and manuka/kanuka honey. These growth- and biofilm-inhibitory
concentrations of manuka-type honeys are the same as those observed for cells that had
not previously been treated with these honeys. These results indicating that planktonic cells
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Table 3 Resistance of S. aureus cells recovered from biofilms after 8% manuka honey treatmentsa.
Honey (%) Type of assay Manuka honey Medihoney Manuka/kanuka
honey
Growth
√ √ √
0
Biofilm formation
√ √ √
Growth × × √
8
Biofilm formation × √ √
Growth × × ×
16
Biofilm formation × × ×
Notes.
a A tick means that there was normal growth or biofilm formation and a cross means that there was no growth or no
bioflm formation.
released from the biofilms with exposure to sub-inhibitory concentrations did not acquire
resistance to the same honey treatment.
DISCUSSION
Chronic wounds are costly and difficult to treat (Hoyle & Costerton, 1991; Ranall et al.,
2012; Sen et al., 2009), and bacterial biofilms are important contributors to the delay in
healing. Honey is a promising alternative treatment for these wounds, and studies have
indicated that it is able to prevent bacterial biofilms and eliminate established biofilms
in vitro (Alandejani et al., 2008; Maddocks et al., 2013; Maddocks et al., 2012; Majtan
et al., 2013). However, the effective concentration of honey reported by these studies
varies significantly, making it hard to establish a foundation for the efficacy of honey on
chronic wound-associated bacterial biofilms in the clinic. This is probably largely due to
the fact that, in most of these studies, very little information is reported on the honey itself,
including the floral source, geographic location, storage conditions, and the level of the
two principle antibacterial components, MGO and hydrogen peroxide. Here we utilize a
suite of well-defined NZ honeys, including manuka-type honeys (manuka, Medihoney
and manuka/kanuka honey) and clover honey, to investigate their anti-biofilm activity
on a range of S. aureus biofilms that differ in their ability to form biofilms. We show
that manuka-type honeys can be used to kill all MSSA and MRSA cells when present as
a biofilm in a chronic wound, supporting the use of this honey as an effective topical
treatment for chronic wound infections.
Our study has shown that prevention of S. aureus biofilm formation occurred at honey
concentrations that also inhibit planktonic growth (Figs. 3A–3D; Table 2), suggesting that
biofilm prevention was a consequence of planktonic growth inhibition, as opposed to any
specific effects on biofilm development. Other studies have also shown that manuka-type
honeys can inhibit bacterial biofilm formation, however, the concentrations required were
higher than those reported to inhibit growth (Alandejani et al., 2008; Maddocks et al.,
2013; Maddocks et al., 2012; Majtan et al., 2013).
We found that higher concentrations of all honeys were necessary to eliminate
established biofilms compared to those needed for prevention, as assessed by both
quantification of biofilm biomass and cell viability. Manuka honey was the most effective,
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closely followed by both Medihoney and manuka/kanuka honey. Elimination of biofilms
was visually confirmed using CLSM of fluorescently-stained live and dead cells. The sugar
content of honey clearly mediates some effect, as sugar solution and clover honey were able
to eliminate established biofilms at high concentrations (32%), as has been shown in other
studies (Chirife et al., 1983; Chirife, Scarmato & Herszage, 1982). However, manuka-type
honeys consistently achieved biofilm elimination at lower concentrations, suggesting
that components specifically within manuka-type honeys contribute towards biofilm
elimination. The concentrations of manuka-type honeys that show significant anti-biofilm
activity are easily achievable in the clinic, since honey dressings typically contain >80%
honey (Cooper et al., 2010).
The use of assays for total biofilm biomass and cell viability to examine the effects of the
various treatments on biofilm elimination afforded some other interesting observations.
We observed that in some cases, sub-inhibitory concentrations of two of the manuka-type
honeys enhanced biofilm formation; however, cell viability did not increase. This could
be due to a stress response, as has been previously observed when bacteria are exposed to
sub-inhibitory concentrations of antibiotics (Haddadin et al., 2010; Kaplan et al., 2012;
Mirani & Jamil, 2011; Subrt, Mesak & Davies, 2011). In other cases, no reduction of biofilm
biomass was observed but cell viability was significantly reduced. This suggests that unlike
antibiotics, the manuka-type honeys (or active components therein) are able to penetrate
through the biofilm matrix, killing the bacterial cells whilst leaving intact matrix.
It is believed that MGO is the primary component in manuka-type honeys responsible
for its anti-biofilm activity (Jervis-Bardy et al., 2011; Kilty et al., 2011). The effectiveness of
the different manuka-type honeys tested here did increase with MGO content. However,
the same degree of biofilm prevention and elimination could not be reproduced with
equivalent amounts of MGO either alone or in combination with sugar. In the case of
prevention, MGO alone was generally ineffective, although a significant amount of biofilm
prevention was achieved in combination with sugar. This suggests that the MGO and sugar
do contribute to biofilm prevention, but their effects are not as strong as those observed
with manuka honey.
Unlike the three NZ manuka-type honeys, neither MGO alone nor MGO with sugar at
honey-equivalent concentrations showed significant S. aureus biofilm elimination. This
indicates that the ability of manuka-type honeys to eliminate biofilms of this organism
is due to one or more components present in the honey other than MGO and sugar,
such as low pH, hydrogen peroxide, phenolics and other unknown components (Jagani,
Chelikani & Kim, 2009; Jervis-Bardy et al., 2011; Kilty et al., 2011; Zmantar et al., 2010).
Interestingly, while the kanuka/manuka honey had a relatively high rate of hydrogen
peroxide production compared to the manuka and Medihoney (Table 1), but low MGO
levels, it was not any more active against biofilms of S. aureus. This suggests that, at least
for this organism, hydrogen peroxide within these manuka-type honeys does not provide
significant anti-biofilm activity.
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CONCLUSIONS
This study is the first to use a suite of well-characterized manuka-type honeys against a
range of strains of S. aureus that differ in their ability to form biofilms. We demonstrate
that: (1) at very low levels, some honeys can enhance biofilm formation, presumably
by evoking a stress response similar to that seen with some antibiotics; (2) the ability
to prevent or eliminate biofilms is influenced by MGO levels and the presence of sugar,
but these alone do not account for all of the anti-biofilm effect; (3) honey is able to
reduce biofilm mass and also to kill cells that remain embedded in the biofilm matrix;
and (4) planktonic cells released from biofilms following honey treatment do not have
elevated resistance to honey. Taken together our results show that if used at an appropriate
therapeutic level, manuka-type honey can be used to kill S. aureus when present as a
biofilm in a chronic wound, supporting the use of this honey as an effective topical
treatment for chronic wound infections.
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